in canada in 2019, it is estimated that 224.000 new cancer cases will be diagnosed and about 1 in 2 Canadians will develop cancer in their lifetime. 2.1 million canadians, or 7.1% of the population, aged 12 years and older are living with cancer or have had cancer over the course of their life. by 2040, cancer incidence is expected to rise to 382.270.
for many canadians diagnosed with cancer today, access to timely and appropriate therapies and molecular testing are not always available, with accessibility varying widely across the country. access challenges such as pricing, reimbursement or limited availability, or lack of awareness and education amongst patients and healthcare professionals may be the cause. and this needs to change.
molecular testing is the key to unlocking these treatments and now is the time for change.
in 2019, throughout the month of november, the cancer collaborative in partnership with the european cancer patient coalition is campaigning for the importance of access to cancer molecular testing and personalized medicine through the “cracking the cancer code” campaign.
we believe that patients living with cancer, regardless of where they live, should have access to the appropriate therapies for them, ensuring better patient outcomes, decreased side effects, improved quality of life, and realizing important cost savings for the healthcare system. this can happen, through access to molecular testing, education and awareness, and access to personalized medicines. promoting better diagnosis, targeted follow up and a truly personalized medicine approach.